Frontiers in Drug Discovery

Frontiers in Drug Discovery

Volume: 2

The Search for Antidepressants - An Integrative View of Drug Discovery

Major depressive disorder (MDD) is a prevalent, chronic, and recurring mental disorder. This disorder is a leading source of disability worldwide, and is associated with excess mortality rates. ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Monoamine Oxidase-A: A Valid Target for the Management of Depression

Pp. 126-134 (9)

Bijo Mathew and Jerad Suresh

Abstract

Monoamine oxidase enzyme has been developed as a valid target for the treatment of depression. The development of selective and reversible type of monoamine oxidase-A inhibitors still remains a challenge to medicinal chemists pursuing the research towards the search of innovative chemotypes for the management of depressive states. The present chapter focuses on the history of MAO-A inhibitors, structure and biochemistry of MAO-A. It also covers challenges involved in the drug development of MAO-A inhibitors.

Keywords:

Adrenaline, Chees effect, Depression, FAD/Dopamine, Inhibitor binding cavity, MAO-A, MAO-B, Moclobemide, Tranylcypromine.

Affiliation:

Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad 678557, Kerala, India.